Mathew Blackman

Stock Analyst at Stifel

(3.43)
# 974
Out of 5,124 analysts
61
Total ratings
60.47%
Success rate
15.35%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Mathew Blackman

Inogen
May 8, 2025
Maintains: Hold
Price Target: $10$7
Current: $6.72
Upside: +4.17%
Tandem Diabetes Care
May 1, 2025
Maintains: Buy
Price Target: $60$31
Current: $21.98
Upside: +41.04%
Penumbra
Apr 24, 2025
Maintains: Buy
Price Target: $301$318
Current: $310.91
Upside: +2.28%
ClearPoint Neuro
Apr 1, 2025
Maintains: Buy
Price Target: $19$25
Current: $13.68
Upside: +82.75%
Beta Bionics
Feb 24, 2025
Initiates: Buy
Price Target: $25
Current: $30.47
Upside: -17.95%
Insulet
Feb 21, 2025
Maintains: Hold
Price Target: $245$293
Current: $284.24
Upside: +3.08%
Globus Medical
Feb 21, 2025
Maintains: Buy
Price Target: $92$94
Current: $87.31
Upside: +7.66%
Orthofix Medical
Nov 8, 2024
Upgrades: Buy
Price Target: $18$24
Current: $15.16
Upside: +58.31%
Cerus
Oct 17, 2024
Maintains: Buy
Price Target: $6$3
Current: $2.06
Upside: +45.63%
DexCom
Aug 23, 2024
Maintains: Buy
Price Target: $90$100
Current: $66.37
Upside: +50.67%
Maintains: Buy
Price Target: $19$16
Current: $21.04
Upside: -23.95%
Downgrades: Hold
Price Target: $18$11
Current: $9.96
Upside: +10.44%